• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    S

    Susan G. Komen Breast Cancer Foundation

    EST. 1982
    50论文总数
    2,018引用总数

    Susan G. Komen (formerly known as Susan G. Komen for the Cure; originally as The Susan G. Komen Breast Cancer Foundation; often simply as Komen) is a breast cancer organization in the United States.Komen focuses on patient navigation and advocacy, providing resources for breast cancer patients to understand the American medical system. It has also funded research into the causes and treatment of breast cancer. However, the organization has been mired by controversy over pinkwashing, allocation of research funding, and CEO pay. Its revenue and public perception have steeply declined since 2010.

    论文量&引用量时间轴

    机构学者

    论文(50)

    年份
    起
    –
    止
    排序
    1Improving Breast Cancer Outcomes Through Quality Care: Call to Action for the Implementation of the Breast Cancer Care Quality Index (BCCQI)
    Maira Caleffi, Mary Ajango, Aydah M Al-Awadhi, Ricki Fairley, Andrea B Feigl, Ana Rita González,Victoria Harmer, Naveena Nekkalapudi, Toyin Saraki, Victoria Wolodzko Smart, Araceli Fernandez-Cerdeño, João Victor Rocha,

    Breast cancer is the most common cancer among women worldwide and a leading cause of mortality. Stark differences in outcomes across income levels, regions, population groups, and healthcare systems reflect deep inequities in access to early detection, diagnosis, and treatment. Due to remarkable scientific advances and many global initiatives, breast cancer is often perceived as a “finished agenda”. This Call to Action, led and endorsed by a multidisciplinary panel of international experts in breast cancer care, policy, and healthcare systems, provides a structured approach to guide countries in improving breast cancer care through the Breast Cancer Care Quality Index (BCCQI), a unified, expert-endorsed tool that translates broad guidance into practical metrics. The Call to Action outlines a framework for country profiling across the BCCQI dimensions: early detection, timely diagnosis, comprehensive management, and strong and resilient healthcare systems. Applying a structured self-assessment matrix linked to tiered recommendations, the Call to Action supports country performance assessment and the development of context-sensitive roadmaps for concrete interventions. By linking assessment to actionable guidance, the Call to Action underscores the urgency of coordinated national efforts and international support to close existing gaps and accelerate progress toward high-quality breast cancer care for all patients.

    2026International journal of environmental research and public health(2026)
    引用
    AI阅读
    加入学术空间
    2Abstract PS3-01-24: Results of a Training Workshop for Genetic Counseling Students on Improving Patient Research Literacy and Engagement in Clinical Research
    S. J. Friedman, R. H. Pugh Yi, M. Dean, P. L. Welcsh, K. N. Owens, J. D. Rogers, D. B. Rose, E. Kuhn

    New cancer treatment and prevention strategies have led to an increase in clinical trials enrolling people with germline mutations linked to cancer risk. Yet, referral of patients remains low. In a FORCE survey, 14% of respondents at high risk for breast cancer were told by their healthcare providers about clinical research opportunities, while 75% expressed interest1. In a survey of genetic counselors, most had never referred breast cancer survivors (63%) or metastatic patients (69%) to clinical trials, and 55% listed research jargon/health literacy as barriers to referral2. We developed a training for genetic counseling students consisting of a presentation, activities and group discussions on factors that impede patients’ ability to find, understand, and enroll in hereditary cancer research, and ways that genetic counselors can address these barriers. We introduced tools to help people find research studies, including FORCE’s "Search and Enroll Tool" that provides plain-language descriptions of studies enrolling people with inherited mutations. We conducted 17 workshops for genetic counselor training programs, and trained 256 students. Almost half completed feedback surveys. Three training program directors participated in post-training interviews. Students indicated that they plan to apply what they had learned in practice. They appreciated the plain-language features of FORCE's tool and how it prioritizes studies enrolling people with germline mutations, and they plan to use the tool to connect patients to research opportunities. Course directors agreed that the training was appropriate to integrate into their curricula. They valued the fact that the training helps students recognize the importance of sharing clinical research opportunities with patients, teaches students how to find this information and present it to patients in easy-to-understand terms, and emphasizes the importance of representativeness in research. Students and directors recommended retaining the content, flow and presentation approach, activities and discussions, and emphasis on the practical application of material presented. Suggestions included limiting the training to 90 minutes, providing more hands-on experience with finding and discussing studies with patients, and developing a version that students can complete on their own. Students and faculty found the training to be informative, relevant, and engaging. Genetic counseling training programs could benefit from training on this critical topic that may not be offered elsewhere in their curricula. In addition to learning information and skills related to finding and communicating with patients about hereditary cancer research, students and faculty agreed that FORCE’s Search and Enroll Tool is useful for matching patients to relevant research opportunities. S. J. Friedman, R. H. Pugh Yi, M. Dean, P. L. Welcsh, K. N. Owens, J. D. Rogers, D. B. Rose, E. Kuhn. Results of a training workshop for genetic counseling students on improving patient research literacy and engagement in clinical research [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS3-01-24.

    2026Clinical Cancer Research(2026)
    引用
    AI阅读
    加入学术空间
    3Abstract PS5-05-18: How Susan G. Komen’s ShareForCures® Research Hub Will Connect Researchers with Real-World Data Shared by Breast Cancer Patients and Survivors in the United States
    K. O. West, J. Epps, E. G. Marks, A. L. Gyden, K. A. Sabelko, M. L. Bondy, J. Jourquin

    To optimize care and improve outcomes for all breast cancer patients, multi-modal data need to be integrated with the experiences of patients. However, access to these datasets that reflect the diversity of patients is often limited and siloed within single institutions. To address these challenges, Susan G. Komen® (Komen) launched ShareForCures® (SFC), a direct-to-consumer, online, IRB-approved breast cancer research registry, designed to integrate real-world, longitudinal data from adults who have been diagnosed with breast cancer and live in the United States and to provide this data for research. We analyzed data from participants who enrolled in SFC within the first two years and developed the SFC Research Hub, which facilitates data exploration, cohort creation and data access application. A taskforce of research experts (clinical oncologists, translational scientists, and research advocates) provided guidance and feedback throughout the development of the SFC Research Hub by completing surveys, meeting with Komen staff, and participating in user testing. From July 2023 to June 2025, 1,214 participants enrolled in SFC (median age = 55 years [range: 27-93], 99% women, 75% non-Hispanic White). Only four participants withdrew after enrollment, resulting in a retention rate of 99.7%. Participants were geographically dispersed across the United States, including Puerto Rico. Most participants received oncology care outside of NCI-designated comprehensive cancer centers and were diagnosed within the past five years. The majority of participants reported their first breast cancer diagnosis as invasive ductal carcinoma (57%), with 39% reporting ER+/HER2- disease. Notably, 18% of participants reported living with metastatic breast cancer (18%) and 14% experienced a recurrence (14%). All participants reported demographic and diagnostic information, and 53% of participants completed additional questionnaires and/or shared saliva samples for germline whole genome sequencing. Medical records were requested for 52% of participants, 30% were retrieved and curated, and 13% have access to a summary of their records in the platform. The SFC Research Hub was designed and developed with end users in mind, offering secure access to integrated, deidentified data shared by SFC participants. To access SFC data, researchers must agree to a code of conduct, acknowledge their institution’s data use agreement with Komen, and receive approval of their data access application describing their research project from Komen. In return, researchers will share their findings with SFC participants. Through SFC, Komen is creating a real-world database that connects researchers with data contributed by participants with diverse experiences. The SFC Research Hub is expected to launch in 2026, enabling researchers to leverage SFC data to enhance our understanding of real-world breast cancer patient experiences, ultimately accelerating discoveries and improving outcomes for all breast cancer patients. K. O. West, J. Epps, E. G. Marks, A. L. Gyden, K. A. Sabelko, M. L. Bondy, J. Jourquin. How Susan G. Komen’s ShareForCures® Research Hub will connect researchers with real-world data shared by breast cancer patients and survivors in the United States [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS5-05-18.

    2026Clinical Cancer Research(2026)
    引用
    AI阅读
    加入学术空间
    4Abstract PS5-11-17: an Integrative Approach to Improving Outcomes for Inflammatory Breast Cancer (IBC) Patients: Creating a Diagnostic Tool, Advocating for ICD-10-CM Codes, and Establishing a Task Force to Address Critical Research Gaps
    L. J. Anstine, A. A. Erwin, M. L. Guthrie, H. D. Baker, S. S. Badve, M. L. Alpaugh, K. A. Sabelko, G. M. Zinser

    Inflammatory Breast Cancer (IBC) is a rare, highly aggressive form of advanced breast cancer that has been historically challenging to diagnose due to its ambiguous clinical nature. A general lack of awareness about IBC within the clinical and patient communities further contributes to delays in diagnosis and treatment. Together, these issues hinder IBC research advancements, leaving patients with limited treatment options and poor prognoses. To address these challenges, Susan G. Komen partnered with IBCRF and the Milburn Foundation to form the IBC Collaborative and launch a multidimensional initiative, aimed at tackling systemic barriers to the advancement of IBC research and care. Early efforts of this initiative prioritized the development of the IBC Scoring System, a quantitative diagnostic scoring rubric for IBC. Available as an easy-to-use online tool (komen.org/ibc-calc), the IBC Scoring System has been steadily gaining global adoption, through the Collaborative’s targeted efforts to raise awareness including dissemination of informational pamphlets for clinician and patient communities. To date, the tool has been used by over 5300 users in more than 100 countries. Additionally, IBC-dedicated clinics, multi-institutional IBC networks and community oncology centers have reported using the tool to support clinical decision making when considering ambiguous patient cases. Recent validation studies have demonstrated that the system can distinguish IBC from non-IBC patients (AUC-ROC 0.84; 95% CI: 0.82 - 0.87) (Lynce et al. JNCI. 2025). Efforts to further enhance the clinical utility of this important diagnostic system are underway and funded by Komen. With a diagnostic system in hand, Komen led advocacy efforts to pursue formal disease recognition through the creation of IBC-specific diagnosis codes. By engaging with the U.S Centers for Disease Control and Prevention (CDC), three unique ICD-10-CM diagnosis codes for IBC (C50.A0, C50.A1, and C50.A2) were approved. Effective October 2025, the widespread utilization of these codes is expected to enhance the ability to track IBC incidence by facilitating inclusion in national health datasets and to improve the coordination of multidisciplinary care for IBC patients. In parallel, a task force was formed to identify current scientific barriers limiting research advancements in IBC and to provide tangible recommendations to address them. Through a series of structured working meetings, three overarching areas emerged as needing significant investigation and investment to drive progress in the biology of IBC: (1) onset and development, (2) detection and monitoring and (3) metastatic dissemination. The group identified a dearth of available IBC tools and resources as key barriers to progress with data silos and the lack of open-access data remaining major obstacles in the field. Additionally, the group prioritized research areas with high potential to improve the understanding and management of IBC. This integrative approach has made significant strides in supporting IBC research, diagnosis and care through the development of a validated diagnostic tool, the establishment of ICD-10-CM codes for IBC, and by defining critical research gaps and prioritizing resolutions. Continued momentum in these areas should ultimately lead to improved outcomes for people with IBC. L. J. Anstine, A. A. Erwin, M. L. Guthrie, H. D. Baker, S. S. Badve, M. L. Alpaugh, K. A. Sabelko, G. M. Zinser. An integrative approach to improving outcomes for inflammatory breast cancer (IBC) patients: creating a diagnostic tool, advocating for ICD-10-CM codes, and establishing a task force to address critical research gaps [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS5-11-17.

    2026Clinical Cancer Research(2026)
    引用
    AI阅读
    加入学术空间
    5Abstract PS4-11-10: Patient-centric Development of Shared Decision-Making Aids: the ASSESS Online Personalized Early Breast Cancer Treatment Decision Support Tool and Resource Website
    B. A. Kerr, J. D. Alexander, H. Zhao, M. Marczyk, L. C. Crocker, A. A. Erwin, E. Kuhn, H. Baker, S. Vaidhyanath, T. Polischuk, K. A. Sabelko, L. Pusztai,

    People newly diagnosed with breast cancer spend a considerable amount of time researching their diagnosis, treatment options and associated side effects. Even with access to trusted evidence-based information, such as Susan G. Komen’s About Breast Cancer pages (https://www.komen.org/breast-cancer/), patients and doctors may struggle to account for the many factors in an individual's unique diagnosis that influence treatment and outcomes, making it hard to balance the potential benefits of therapy with the risks of side effects on a personalized basis. The discontinuation of the popular Adjuvant! Online tool compounded this challenge, creating a need for a new, publicly available tool to provide survival estimates for the early-stage breast cancer population in the U.S. To address this, Komen collaborated with teams from MD Anderson and Yale Cancer Centers to develop a web-based decision support tool that provides personalized five-year survival estimates for women with early-stage breast cancer. The tool, ASSESS, uses an algorithm developed with U.S.-based SEER data to estimate outcomes for various systemic adjuvant therapies based on an individual’s clinical and pathological characteristics. The ASSESS online tool was designed and built by a multidisciplinary team of experts, including scientists, clinicians, website developers and marketing professionals, using an iterative approach to incorporate feedback from patient advocates and breast cancer clinicians. Initial design requirements for ASSESS included a simple and engaging user interface and being both public-facing and suitable for use in a clinic as a shared decision-making tool. It was designed to be responsive and support use on multiple devices, incorporating best practices for communicating risks, and offering a summary feature to save and print results.Cognitive interviews were conducted with patient advocates and breast cancer clinicians to inform the design of the tool, resulting in changes that made the interface and results output clearer and more accessible to a lay audience. Once finalized, additional usability testing was conducted with patient advocates and breast cancer medical oncologists to ensure the tool was deployed as intended. Komen hosts the ASSESS tool on komen.org and has developed supporting information to empower those newly diagnosed with breast cancer to make informed decisions by offering tailored treatment options, along with education on each treatment option and how treatment combinations may affect survival. Within the tool, links are provided to Komen-generated and expert-vetted information that describes the significance of each input requested (age at diagnosis, menopause status, molecular subtype, tumor size/grade, etc.). By integrating these resources, the tool empowers patients by providing sound and understandable information, enabling them to be actively involved in their treatment decisions. The ASSESS tool, publicly launching later this year, should help providers visually demonstrate different treatment option outcomes and provide links to accessible information that can be shared with patients for each treatment, including details on how it works, its side effects, and references to the associated expert clinical guidelines. Built using a patient-centered approach, the ASSESS tool supports shared decision-making for people with early-stage breast cancer, helping them make the best individual decisions for their treatment and care. B. A. Kerr, J. D. Alexander, H. Zhao, M. Marczyk, L. C. Crocker, A. A. Erwin, E. Kuhn, H. Baker, S. Vaidhyanath, T. Polischuk, K. A. Sabelko, L. Pusztai, S. H. Giordano, R. J. Volk, G. M. Zinser. Patient-centric development of shared decision-making aids: The ASSESS online personalized early breast cancer treatment decision support tool and resource website [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS4-11-10.

    2026Clinical Cancer Research(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 50 篇论文

    合作机构(92)

    德克萨斯大学奥斯汀分校合作论文 3
    印第安纳大学合作论文 3
    LUNGevity Foundation合作论文 2
    罗文大学合作论文 2
    Perelman School of Medicine at the University of Pennsylvania合作论文 1
    霍华德·休斯医学研究所合作论文 1
    达纳 - 法伯癌症研究所合作论文 1
    科隆大学合作论文 1
    Zurich Insurance Group (Switzerland)合作论文 1
    斯洛伐克技术大学合作论文 1

    机构统计